Medix21 expands DED portfolio
Medix21's Aaron Morgan (left) and Camille Furnandiz (third) with Abigail Faitala and Kristine Laxamana

Medix21 expands DED portfolio

June 7, 2022 Staff reporters

Medix21 now offers a full suite of dry eye consumables following the introduction of the Eyestil Synfo dry eye disease (DED) drop.

 

New to New Zealand, the Eyestil Synfo dry eye drop was developed by Italian ophthalmic company Sifi, supplier of Medix21’s innovative extended depth of focus intraocular Mini Well lenses and a long-term supporter of the Tear Film and Ocular Surface organisation, which leads the international fight against ocular surface disease, said Medix21’s Camille Furnandiz. “The drop is a completely new hypotonic formulation, blending sodium hyaluronate and xanthan gum with two osmoprotectants, betaine and glycine, giving it better osmo-protective and re-epithelising qualities, as well as better lubrication, to protect the ocular surface.”

 

Aimed at patients with all types of moderate to severe dry eye, it’s also preservative free, has a six-month shelf life once opened, is compatible with contact lenses and will only be sold in New Zealand through eyecare practices, she said, so a patient’s eyecare professional can monitor their care.

 

“It’s a whole new area of speciality for Medix21, which perhaps we wouldn’t have got into except we found such an amazing product,” said Medix21’s Aaron Morgan. The company now has a complete dry eye disease consumable offering with the Synfo drops, AmnioTek’s amniotic membrane grafts and Lacrivera’s dry eye compress and punctal and canalicular plugs, he said.